Bill > SB43

This bill establishes a framework for psychedelic-assisted therapy in Louisiana, defining key terms like "academic health center" (an institution with a medical school and teaching hospitals), "drug developer" (a company involved in creating medications), "ibogaine" (a specific psychedelic substance and its related treatments), "psychedelic medication" (which includes ibogaine, psilocybin, and similar substances), and "psychedelic-assisted therapy" (the administration of these medications in a controlled setting with preparatory and integrative psychotherapy). It creates a Psychedelic-Assisted Therapy Initiative within the Louisiana Department of Health to identify academic health centers conducting clinical studies for conditions like opioid use disorders and treatment-resistant mental health issues, and to help identify eligible patients through human service districts and potentially using opioid settlement funds. Participating academic health centers must adhere to strict federal regulations, including having FDA investigational new drug applications, Institutional Review Board approval, and detailed plans for drug administration, safety, and clinician qualifications. The bill also allows academic health centers to partner with drug developers to conduct clinical trials for ibogaine, aiming for FDA approval for treating opioid use disorder and other conditions, with specific revenue-sharing agreements for any intellectual property developed.

Budget and Finance, Health and Social Services

https://www.legis.la.gov/legis/BillInfo.aspx?s=26rs&b=SB43&sbi=y